Back to Online Symposia Home Page
|
|
Program Description
Long-term therapy is a necessary requirement for most patients with schizophrenia; however, effective treatments that maintain efficacy with minimal adverse effects can be a difficult balance to achieve. It is important that treatments minimize side effects so that they do not contribute to discontinuations or deficits in patient functionality, as these will impact the patients' well-being.
Learning Objectives
By participating in this activity, you will be able to:
- Identify three common medical vulnerabilities in patients with schizophrenia
- Describe three ways of how metabolism affects patients with schizophrenia
- Identify challenges associated with polypharmacy and three interactions to which schizophrenia patients are inherently vulnerable
Who Will Benefit
This activity was designed to meet the continuing education needs of psychiatrists and other physicians, physician assistants, registered nurses, psychiatric nurses and advanced practice nurses. Other mental health professionals may find this activity informative and should check with their state licensing and certification boards to determine if it meets their continuing education requirements.
Your Distinguished Faculty
Understanding the Impact of Comorbid Conditions in Schizophrenia
Donald C. Goff, MD
Associate Professor of Psychiatry, Harvard Medical School
Director, Schizophrenia Program, Massachusetts General Hospital
Faculty Disclosures
Donald C. Goff, MD, receives grants/research support and honoraria from Pfizer Inc. He also receives honoraria from Eli Lilly and Company, Bristol-Myers Squibb Company, VerusMed, Letters and Science, Primedia, SG Cowen, and Vista Research. Dr. Goff also receives grants and research support from Cephalon, Inc., and Janssen, L.P. He is also a consultant for Xenoport, Dainippon Sumitomo Pharma America, Inc., and is on the advisory board for Solvay, Wyeth Pharmaceuticals, and Bristol-Myers Squibb Company.
Balancing the Efficacy and Safety of Pharmacotherapy: Metabolism, Interactions and Polypharmacy
John P. Docherty, MD
Adjunct Professor of Psychiatry, Joan and Sanford I. Weill Medical College, Cornell
Faculty Disclosures
John P. Docherty, MD, has been a member of the Speakers Bureau for Abbott, Forest Pharmaceuticals, Inc., Janssen, L.P., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Sepracor, and Pfizer Inc. He has received grants and research support from Abbott, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen, L.P., Pfizer Inc., and AstraZeneca. In addition, he has been a consultant for Janssen, L.P.
|
Commercial Support
Supported through an educational grant by Janssen, L.P., administered by Ortho-McNeil Janssen Scientific Affairs, LLC
Disclaimers
The content of this video activity may include product information that is inconsistent with or outside of the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer's product information.
To earn continuing education credit, view this online course and complete the posttest and evaluation provided. A passing score of 70% or more must be achieved on the posttest. A link is provided within this online activity to access the posttest and evaluation. You will have the option of printing a Statement of Credit for your records after submission of the evaluation.
CME LLC, Janssen, L.P., and Ortho-McNeil Janssen Scientific Affairs, LLC are not responsible for the speaker's statements, materials, acts or omissions. |
|
Continuing Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME credits from activities presented by ACCME accredited providers may be used toward American Osteopathic Association (AOA) Category 2-A requirements.
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
CME LLC is approved by the California Board of Registered Nursing, Provider No. CEP12748, and designates this educational activity for 1.0 contact hour for nurses.
The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ toward recertification requirements.
Content Originally Presented: October 11, 2007
Online Date: December 17, 2007
Credit Expiration Date: December 16, 2008
This activity is based on the symposium Optimizing Therapy in Schizophrenia: Understanding the Impact of Pharmacokinetic Properties of Current and Emerging Therapies at the 20th Annual U.S Psychiatric and Mental Health Congress in October, 2007 in Orlando, Fla. Participants who attended the live symposium mentioned above cannot claim credit for this activity.
|
